I just finished reading the NEJM paper on BE-CAR7, and I think it's one of the most interesting advances for T-cell ALL in years.

For a long time, CAR-T therapy transformed outcomes for B-cell ALL, but T-cell ALL remained a major challenge because the target (CD7) is also present on the therapeutic T cells themselves. The engineered cells would attack each other—a problem known as fratricide.

The researchers addressed this by using base editing rather than conventional gene editing to modify donor T cells before creating the CAR-T product.

The edited cells had several changes, including removal of CD7, allowing the CAR-T cells to survive long enough to attack leukemia cells.

In this early clinical report, three children with relapsed/refractory T-ALL—who had exhausted standard treatment options—achieved complete remission after treatment with BE-CAR7.

Of course, this was a very small study. It doesn't prove a cure, and much longer follow-up is needed before we know how durable these responses will be.

Still, it feels like an important proof of concept for T-cell malignancies, where progress has historically lagged behind B-cell disease.

I'm curious what others think.

Do you believe base-edited CAR-T could eventually become a standard option for relapsed T-ALL, or are there still too many unanswered questions?